Anthropic unveiled Claude Science on Tuesday, a public beta AI workbench that gives scientists a single interface to run computational pipelines, query more than 60 scientific databases, and track every result with full provenance. The launch targets the tedious, time-consuming tasks in biomedical research and drug development that often delay breakthroughs, and arrives as AI-enabled workflows in drug discovery have already cut preclinical candidate stage time by up to 40% and costs by 30%, according to a June report from law firm Foley Hoag.
Claude Science is not a new frontier AI model. Anthropic described it as a workbench that combines scientific tools, database connections, and compute integrations with existing Claude model plans. The tool handles tasks that typically slow down Research workflows - literature review, data analysis, and manuscript preparation - while managing compute environments for each user and saving full provenance on every result. That evidentiary record means scientific findings remain traceable and reproducible across teams.
"General AI assistants can discuss biology, but they can't run a pipeline, navigate scientific databases, orchestrate cluster jobs or keep track of what happened in a previous session," Anthropic said in its announcement.
The workbench includes analysis specialists for genomics, single-cell, proteomics, structural biology, cheminformatics, and other domains. It connects natively to more than 60 scientific databases and domain-specific open models, letting researchers query external data without leaving the interface.
Internal drug discovery push
During a conference in San Francisco on Tuesday, company executives also revealed that Anthropic is launching an internal drug discovery program focused primarily on neglected diseases, according to CNBC. The company plans to develop AI tools designed for bio-pharmaceutical firms. Anthropic did not immediately respond to a request for additional details about Claude Science or the internal drug discovery effort.
The global AI in the life sciences market was valued at roughly $17 billion in 2025 and is projected to reach $69 billion by 2031, Foley Hoag reported. That growth reflects mounting pressure on pharmaceutical companies and research institutions to reduce both the time and expense of bringing therapies to patients.
Industry momentum builds
The race to apply AI for Science & Research has drawn major players across technology and healthcare. Last month, Microsoft and Mayo Clinic revealed a collaboration on a healthcare-specific frontier AI model designed to help clinicians make earlier diagnoses and deliver more personalized treatments. Meanwhile, drug makers including Eli Lilly and Novo Nordisk are running their own AI initiatives, and the U.S. Food and Drug Administration is piloting AI for real-time clinical trials.
Nii Osae, CEO and founder of Mindbeam AI, said the biggest advantage AI brings to life sciences is speed - particularly for research, molecular synthesis, and analysis. "Research in life sciences often requires an ensemble of tools to perform various tasks in each experimental pipeline," Osae said. That tool sprawl increases both cost and time to confirm hypotheses and implement procedures. Agentic AI tools, he added, shorten repetitive scientific tasks and reduce the time to solution convergence.
Deciding what moves forward
Darren Kimura, CEO and president of AI infrastructure provider AISquared, said the real bottleneck is not discovery itself. "Most researchers I speak with say the biggest bottleneck is deciding which of the many discoveries are ready to move forward, how to test them rigorously, how to accelerate regulatory approval and how to do so more cost-effectively," Kimura said. AI can help researchers prioritize which compounds, hypotheses, or trials deserve attention, surface gaps in evidence, and identify risks earlier.
"It can help organize prior research, surface gaps in evidence, identify risks earlier, and reduce the manual burden around documentation and analysis," Kimura said. "The goal should be to help scientists move faster through validation with stronger evidence and better reproducibility."
Governance and human oversight
Both experts cautioned that AI's benefits in life sciences depend on strong governance and human oversight. "Since current AI tools are prone to hallucination, results from these systems should be auditable with human-in-the-loop guardrails to ensure high validity and safety of the results," Osae said. Patient data governance carries equal weight, he added, since patient data serves as input to train and improve the AI models used in research pipelines. Proper governance reduces the risk of therapeutic bias that could stem from over-reliance on model output without balancing it against real-world evidence.
Kimura struck a similar note. "The winners in life sciences AI will not simply be the companies with the most powerful models," he said. "They will be the organizations that make AI usable, auditable, secure and trusted inside real scientific and regulated environments."
Why this matters for Science and Research professionals
Claude Science signals a shift from general-purpose AI assistants toward domain-specific workbenches that fit into existing scientific workflows. For researchers, the practical takeaway is that AI tools are beginning to handle the connective tissue of lab work - database queries, provenance tracking, and compute orchestration - not just the conversational layer. The time savings claimed by early adopters of AI in drug discovery - 40% at the preclinical candidate stage - are concrete enough to warrant attention. But the experts quoted here are clear: the tools are only as good as the auditability and governance wrapped around them, and labs that treat AI output as a starting point for human review, rather than a final answer, will be better positioned as these tools mature.
Your membership also unlocks:
